Literature DB >> 29236585

Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.

Lara Evellyn do Macedo1, Viviane Matos Ferreira1,2, Caroline Alves Feitosa1, Amélia Maria Pithon Borges Nunes2, Leila Carvalho Campos2, Marco Aurélio Palazzi Sáfadi3.   

Abstract

The significant increase in the incidence rates and ongoing outbreaks of serogroup C meningococcal (MenC) disease, associated with the sequence type-103 complex, motivated the incorporation of the meningococcal C conjugate (MCC) vaccine in the routine immunization program in the State of Bahia, Brazil in early 2010, targeting children younger than 5 years of age. In its capital, Salvador, the program also included a catch-up campaign for individuals 10-24 years of age. We performed an observational, ecological study, analyzing data collected from 2007 to 2015, to compare the impact of these two immunization strategies on meningococcal disease incidence and mortality rates. In Salvador, following the vaccination program, a dramatic early impact on MenC disease and mortality rates could be observed, with significant reductions in incidence rates of MenC disease in all age groups, including individuals that were too old to have been vaccinated, indicating the presence of herd protection. Compared to the pre-vaccine period, a virtual disappearance of MenC disease was observed in 2015. However, in the state of Bahia (excluding the city of Salvador), no herd protection could be observed, with significant impact only among vaccine-eligible children within 5 years of introduction of the MCC vaccination program. These results highlight the importance of catch-up campaigns, including adolescents and young adults, to induce herd protection compared to immunization strategies restricted to infants and young children. This information is crucial for identifying optimal immunization policies and future strategies, focused on adolescents, to optimize the impact of MCC vaccination programs.

Entities:  

Keywords:  Meningococcal disease; Neisseria meningitidis; adolescent; herd protection; meningococcal conjugate vaccines; surveillance

Mesh:

Substances:

Year:  2018        PMID: 29236585      PMCID: PMC5989881          DOI: 10.1080/21645515.2017.1415682

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  43 in total

Review 1.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

Review 2.  Meningococcal carriage by age: a systematic review and meta-analysis.

Authors:  Hannah Christensen; Margaret May; Leah Bowen; Matthew Hickman; Caroline L Trotter
Journal:  Lancet Infect Dis       Date:  2010-11-11       Impact factor: 25.071

Review 3.  Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs.

Authors:  Marco Aurelio P Sáfadi; Eitan N Berezin; Luiza Helena F Arlant
Journal:  J Pediatric Infect Dis Soc       Date:  2014-04-25       Impact factor: 3.164

4.  Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015.

Authors:  I Parent du Chatelet; A E Deghmane; D Antona; E Hong; L Fonteneau; M K Taha; D Lévy-Bruhl
Journal:  J Infect       Date:  2017-03-07       Impact factor: 6.072

5.  A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.

Authors:  Merijn W Bijlsma; Matthijs C Brouwer; Lodewijk Spanjaard; Diederik van de Beek; Arie van der Ende
Journal:  Clin Infect Dis       Date:  2014-07-28       Impact factor: 9.079

6.  Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.

Authors:  Shamez N Ladhani; Kazim Beebeejaun; Jay Lucidarme; Helen Campbell; Steve Gray; Ed Kaczmarski; Mary E Ramsay; Ray Borrow
Journal:  Clin Infect Dis       Date:  2014-11-10       Impact factor: 9.079

7.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 8.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

Review 9.  The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.

Authors:  Ray Borrow; Pedro Alarcón; Josefina Carlos; Dominique A Caugant; Hannah Christensen; Roberto Debbag; Philippe De Wals; Gabriela Echániz-Aviles; Jamie Findlow; Chris Head; Daphne Holt; Hajime Kamiya; Samir K Saha; Sergey Sidorenko; Muhamed-Kheir Taha; Caroline Trotter; Julio A Vázquez Moreno; Anne von Gottberg; Marco A P Sáfadi
Journal:  Expert Rev Vaccines       Date:  2016-11-22       Impact factor: 5.217

10.  An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015.

Authors:  Jay Lucidarme; Kevin J Scott; Roisin Ure; Andrew Smith; Diane Lindsay; Bianca Stenmark; Susanne Jacobsson; Hans Fredlund; J Claire Cameron; Alison Smith-Palmer; Jim McMenamin; Steve J Gray; Helen Campbell; Shamez Ladhani; Jamie Findlow; Paula Mölling; Ray Borrow
Journal:  Euro Surveill       Date:  2016-11-10
View more
  1 in total

1.  The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta.

Authors:  David Pace; Charmaine Gauci; Christopher Barbara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-05-16       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.